日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

对肠道微生物组和代谢组与idecabtagene vicleucel疗效和毒性相关性的纵向分析

Satabdi Saha ,Lubna Rehman ,Abdur Rehman ,Faezeh Darbaniyan ,Donna M Weber ,Melody Becnel ,Mahmoud Gaballa ,Sheeba K Thomas ,Hans C Lee ,Chia-Chi Chang ,Reetakshi Arora ,Meghan Menges ,Salvatore Corallo ,Marco L Davila ,Frederick L Locke ,Mark R Tanner ,Sattva S Neelapu ,Elizabeth J Shpall ,Christopher R Flowers ,Robert Z Orlowski ,Robert R Jenq ,Michael D Jain ,Christine Peterson ,Doris K Hansen ,Neeraj Y Saini ,Krina K Patel

Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

ZUMA-7 中二线 axicabtagene ciloleucel 或标准治疗后后续抗淋巴瘤治疗的结果

Armin Ghobadi, Javier Munoz, Jason R Westin, Frederick L Locke, David B Miklos, Aaron P Rapoport, Miguel-Angel Perales, Patrick M Reagan, Joseph McGuirk, Caron A Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O Oluwole4

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

未受抗生素干扰的肠道微生物群与CD19-CAR-T细胞癌症免疫疗法的临床疗效相关。

Christoph K Stein-Thoeringer # ,Neeraj Y Saini # ,Eli Zamir # ,Viktoria Blumenberg # ,Maria-Luisa Schubert # ,Uria Mor ,Matthias A Fante ,Sabine Schmidt ,Eiko Hayase ,Tomo Hayase ,Roman Rohrbach ,Chia-Chi Chang ,Lauren McDaniel ,Ivonne Flores ,Rogier Gaiser ,Matthias Edinger ,Daniel Wolff ,Martin Heidenreich ,Paolo Strati ,Ranjit Nair ,Dai Chihara ,Luis E Fayad ,Sairah Ahmed ,Swaminathan P Iyer ,Raphael E Steiner ,Preetesh Jain ,Loretta J Nastoupil ,Jason Westin ,Reetakshi Arora ,Michael L Wang ,Joel Turner ,Meghan Menges ,Melanie Hidalgo-Vargas ,Kayla Reid ,Peter Dreger ,Anita Schmitt ,Carsten Müller-Tidow ,Frederick L Locke ,Marco L Davila ,Richard E Champlin ,Christopher R Flowers ,Elizabeth J Shpall ,Hendrik Poeck ,Sattva S Neelapu ,Michael Schmitt ,Marion Subklewe ,Michael D Jain ,Robert R Jenq ,Eran Elinav

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

ZUMA-2 研究中对复发/难治性套细胞淋巴瘤患者(包括高风险亚组)进行 KTE-X19 的三年随访

Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn, Peter A McSweeney, David B Miklos, John M Pagel, Marie José Kersten, Krimo Bouabdallah, Rashmi Khanal, Max S Topp, Roch Houot, Amer Beitinjaneh

Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells

调节多胺/次黄嘌呤轴控制CD8+组织驻留记忆T细胞的生成

Aya G Elmarsafawi ,Rebecca S Hesterberg ,Mario R Fernandez ,Chunying Yang ,Lancia Nf Darville ,Min Liu ,John M Koomen ,Otto Phanstiel 4th ,Reginald Atkins ,John E Mullinax ,Shari A Pilon-Thomas ,Frederick L Locke ,Pearlie K Epling-Burnette ,John L Cleveland

Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

肿瘤免疫结构是抗 CD19 CAR-T 细胞治疗大 B 细胞淋巴瘤疗效的决定因素

Nathalie Scholler, Regis Perbost, Frederick L Locke, Michael D Jain, Sarah Turcan, Corinne Danan, Edmund C Chang, Sattva S Neelapu, David B Miklos, Caron A Jacobson, Lazaros J Lekakis, Yi Lin, Armin Ghobadi, Jenny J Kim, Justin Chou, Vicki Plaks, Zixing Wang, Allen Xue, Mike Mattie, John M Rossi, Ad

Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma

全基因组测序揭示了淋巴瘤抗 CD19 CAR-T 细胞治疗失败背后的复杂基因组特征

Michael D Jain, Bachisio Ziccheddu, Caroline A Coughlin, Rawan Faramand, Anthony J Griswold, Kayla M Reid, Meghan Menges, Yonghong Zhang, Ling Cen, Xuefeng Wang, Mohammad Hussaini, Ola Landgren, Marco L Davila, Jonathan H Schatz, Frederick L Locke, Francesco Maura

CAR-T manufactured from frozen PBMC yield efficient function with prolonged in vitro production

利用冷冻外周血单核细胞 (PBMC) 制备的 CAR-T 细胞具有高效的功能,且体外生产寿命更长。

Julieta Abraham-Miranda ,Meghan Menges ,Reginald Atkins ,Mike Mattie ,Justyna Kanska ,Joel Turner ,Melanie J Hidalgo-Vargas ,Frederick L Locke

Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States

Axicabtagene Ciloleucel 在美国治疗大 B 细胞淋巴瘤的真实世界证据

Caron A Jacobson, Frederick L Locke, Long Ma, Julius Asubonteng, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David Bernard Miklos, Yi Lin, Miguel-Angel Perales, Matthew Alexander Lunning, Megan M Herr, Brian T Hill, Siddhartha Ganguly, Hua Dong, Sarah Nikiforow, Michele Hooper, Jun Kaw

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

CD19 靶向逃避是使用 axicabtagene ciloleucel 治疗的大 B 细胞淋巴瘤复发的机制

Vicki Plaks, John M Rossi, Justin Chou, Linghua Wang, Soumya Poddar, Guangchun Han, Zixing Wang, Shao-Qing Kuang, Fuliang Chu, Richard E Davis, Francisco Vega, Zahid Bashir, Caron A Jacobson, Frederick L Locke, Patrick M Reagan, Scott J Rodig, Lazaros J Lekakis, Ian W Flinn, David B Miklos, Adrian B